Cargando…

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diekstra, MH, Fritsch, A, Kanefendt, F, Swen, JJ, Moes, DJAR, Sörgel, F, Kinzig, M, Stelzer, C, Schindele, D, Gauler, T, Hauser, S, Houtsma, D, Roessler, M, Moritz, B, Mross, K, Bergmann, L, Oosterwijk, E, Kiemeney, LA, Guchelaar, HJ, Jaehde, U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613186/ https://www.ncbi.nlm.nih.gov/pubmed/28571114 http://dx.doi.org/10.1002/psp4.12210

Ejemplares similares

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
por: Diekstra, Meta H. M., et al.
Publicado: (2022)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands
por: Bank, P. C. D., et al.
Publicado: (2019)

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
por: Liu, Xiaoyan, et al.
Publicado: (2016)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
por: Caudle, Kelly E., et al.
Publicado: (2019)

Caffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk
por: Purkiewicz, Aleksandra, et al.
Publicado: (2022)

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Continuous vs bolus administration of imipenem in critically ill patients with ICU-acquired pneumonia
por: Sakka, S, et al.
Publicado: (2004)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics
por: van der Lee, Maaike, et al.
Publicado: (2019)

Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019)

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
por: Perwitasari, D. A., et al.
Publicado: (2011)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
por: Yin, Anyue, et al.
Publicado: (2019)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Tissue pharmacokinetics of individual macrolides support observed differences in development of bacterial resistance
por: Krasniqi, Shaip, et al.
Publicado: (2010)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
por: Sanchez-Spitman, A. B., et al.
Publicado: (2018)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
por: Wilffert, Bob, et al.
Publicado: (2010)

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2015)

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
por: van Laar, S.A., et al.
Publicado: (2022)

Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P.A., et al.
Publicado: (2017)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment
por: Lahmer, Tobias, et al.
Publicado: (2022)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Cannot write session to /tmp/vufind_sessions/sess_8j1qjj3to34t6fk8vvp1ugoa9n